Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centre Hospitalier Universitaire Vaudois | OTHER |
| University Hospital, Geneva | OTHER |
| University of Bern | OTHER |
Not provided
Not provided
Not provided
Not provided
Hospital-acquired venous thromboembolism (HA-VTE) is one of the leading preventable causes of in-hospital mortality, but prevention of VTE in hospitalized medical patients remains challenging, as preventive measures such as pharmacological thromboprophylaxis (TPX) need to be tailored to individual thrombotic risk.
The broad objective of this project is to improve VTE prevention strategies in hospitalized medical patients by prospectively examining VTE risk factors (including mobility) and comparing existing risk assessment models.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Venous thromboembolism | Symptomatic, objectively confirmed fatal and non-fatal hospital-acquired venous thromboembolism, including symptomatic distal and proximal deep vein thrombosis and pulmonary embolism after hospital admission | Within 90 days of initial hospital admission |
| Measure | Description | Time Frame |
|---|---|---|
| Venous thromboembolism | Symptomatic, objectively confirmed fatal and non-fatal hospital-acquired venous thromboembolism, including symptomatic distal and proximal deep vein thrombosis and pulmonary embolism during hospitalization | During the initial hospitalization, an average of 7 days |
| All-cause mortality |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Acutely ill adult patients hospitalized for at least 24h in general internal medicine of the participating tertiary care hospitals
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christine Baumgartner, MD, MAS | Inselspital, Bern University Hospital | Principal Investigator |
| Marie Méan, MD | Centre Hospitalier Universitaire Vaudois, University Hospital of Lausanne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Inselspital, Bern University Hospital | Bern | Switzerland | ||||
| Geneva University Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35609087 | Derived | Choffat D, Farhoumand PD, Jaccard E, de la Harpe R, Kraege V, Benmachiche M, Gerber C, Leuzinger S, Podmore C, Truong MK, Dumans-Louis C, Marti C, Reny JL, Aujesky D, Rakovic D, Limacher A, Rossel JB, Baumgartner C, Mean M. Risk stratification for hospital-acquired venous thromboembolism in medical patients (RISE): Protocol for a prospective cohort study. PLoS One. 2022 May 24;17(5):e0268833. doi: 10.1371/journal.pone.0268833. eCollection 2022. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
All-cause mortality (all causes of death will be considered) |
| During hospitalization (an average of 7 days) and up to 90 days of initial hospital admission |
| Major bleeding | Major bleeding will be defined as fatal bleeding, symptomatic bleeding at critical sites (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome), or bleeding with a reduction of hemoglobin of at least 20 g/L or bleeding leading to transfusion of 2 or more units of packed red blood cells according to the definition of the International Society on Thrombosis and Haemostasis | During hospitalization (an average of 7 days) and up to 90 days of initial hospital admission |
| Clinically relevant non-major bleeding | Clinically relevant non-major bleeding, defined as overt bleeding that does not meet criteria for major bleeding but is associated with a medical intervention, unscheduled physician contact (visit or telephone call), or pain or impairment of activities of daily life | During hospitalization (an average of 7 days) and up to 90 days of initial hospital admission |
| Patient autonomy in the activities of daily living | Patient autonomy in the activities of daily living as assessed by the modified Barthel Index | At discharge (an average of 7 days after initial hospital admission) and at 90 days after admission |
| Length of hospital stay | Length of hospital stay, defined as the time/date of discharge minus time/date of admission at the hospital ward | within 90 days of initial hospital admission |
| Subsequent hospitalizations | Subsequent hospitalization, defined as hospital readmissions | Within 90 days of initial hospital admission |
| Geneva |
| Switzerland |
| University Hospital of Lausanne | Lausanne | Switzerland |
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| D020246 | Venous Thrombosis |
| D011655 | Pulmonary Embolism |
| D016769 | Embolism and Thrombosis |
| D051346 | Mobility Limitation |
| D007049 | Iatrogenic Disease |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D013927 | Thrombosis |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D004617 | Embolism |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
Not provided
Not provided